| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF00405906 |
| P953 | full work available at URL | http://link.springer.com/content/pdf/10.1007/BF00405906.pdf |
| http://link.springer.com/article/10.1007/BF00405906/fulltext.html | ||
| http://link.springer.com/content/pdf/10.1007/BF00405906 | ||
| P698 | PubMed publication ID | 7240346 |
| P2093 | author name string | G. Voelcker | |
| H. J. Hohorst | |||
| T. Wagner | |||
| D. Heydrich | |||
| T. Jork | |||
| P2860 | cites work | pharmacologist | Q2114605 |
| [Studies on the spontaneous decomposition of 4-hydroxyphosphamide and 4-hydroperoxyphosphamide by means of thin-layer chromatography] | Q68941328 | ||
| Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo | Q69551574 | ||
| [Blood level and urinary excretion of activated cyclophosphamide and its deactivation products in man (author's transl)] | Q71143704 | ||
| Fluorometric determination of acrolein and related compounds with m-aminophenol | Q72290253 | ||
| Fluorometric determination of "activated" cyclophosphamide and ifosfamide in blood (author's transl) | Q28327626 | ||
| Cyclophosphamide cystitis—Identification of acrolein as the causative agent | Q28327805 | ||
| Mass spectrometric characterization of activated N-(2-chloroethyl)amino oxazaphosphorine derivative | Q28333075 | ||
| Synthesis of 4-hydroperoxy derivatives of ifosfamide and trofosfamide by direct ozonation and preliminary antitumor evaluation in vivo | Q28333815 | ||
| Studies on the human pharmacokinetics of isophosphamide (NSC-109724) | Q28342614 | ||
| Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide | Q39687321 | ||
| Permeation of cyclophosphamide (NSC-26271) metabolites into tumor cells | Q43535151 | ||
| Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds | Q44523073 | ||
| Isolation and mass spectral identification of blood metabolities of cyclophosphamide: Evidence for phosphoramide mustard as the biologically active metabolite | Q66931110 | ||
| Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans | Q67585033 | ||
| Characterization and quantitative estimation of activated cyclophosphamide in blood and urine | Q67585038 | ||
| Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds | Q67796446 | ||
| The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity | Q67796451 | ||
| Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives | Q67796489 | ||
| Studies on the metabolism of isopnosphamide (NSC-109724) in man | Q67796495 | ||
| Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724) | Q67796499 | ||
| Isolation and characterisation of two main metabolites of ifosfamide from human urine (author's transl) | Q68298984 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| cancer research | Q3421914 | ||
| ifosfamide | Q418560 | ||
| oncology | Q162555 | ||
| P304 | page(s) | 95-104 | |
| P577 | publication date | 1981-01-01 | |
| P1433 | published in | Journal of Cancer Research and Clinical Oncology | Q2081599 |
| P1476 | title | Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test | |
| P478 | volume | 100 |
| Q67864961 | Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study |
| Q69428484 | Analysis of 4-hydroxycyclophosphamide by gas chromatography-mass spectrometry in plasma |
| Q39533747 | Clinical pharmacokinetics of drugs used in the treatment of breast cancer |
| Q39757762 | Comparative activity of ifosfamide and cyclophosphamide |
| Q70589461 | Comparative effects of ASTA Z 7557 (INN mafosfamide) and cyclophosphamide on hematopoiesis in mice |
| Q72678270 | Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy |
| Q55478651 | Determination of 4-hydroxyifosfamide in biological matrices by high-performance liquid chromatography. |
| Q42537311 | Determination of acrolein in human urine by headspace gas chromatography and mass spectrometry. |
| Q34584039 | Dosing and side-effects of ifosfamide plus mesna |
| Q72822733 | Effect of ASTA Z 7557 (INN mafosfamide) a precursor of 4-hydroxy-cyclophosphamide on human T-lymphocytes' Fc-receptors and immunoregulatory functions |
| Q34726639 | Ifosfamide clinical pharmacokinetics |
| Q28324157 | Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer |
| Q36419989 | In vivo detection of ifosfamide by 31P-MRS in rat tumours: increased uptake and cytotoxicity induced by carbogen breathing in GH3 prolactinomas |
| Q44054408 | Influence of mesna and cysteine on the systemic toxicity and therapeutic efficacy of activated cyclophosphamide |
| Q67864968 | Metabolism and pharmacokinetics of oral and intravenous ifosfamide |
| Q44455488 | Non-myeloablative hematopoietic stem cell transplantation for the treatment of adult T-cell lymphoma in a patient with advanced hepatic impairment |
| Q55242390 | Pharmacokinetic approach to rational therapeutic doses for human tumor-bearing nude mice. |
| Q45000857 | Pharmacokinetics and metabolism of cyclophosphamide administered after total body irradiation of bone marrow transplant recipients |
| Q46467130 | Preclinical pharmacokinetics and stability of isophosphoramide mustard |
| Q72032372 | Quantitation of 4-hydroxycyclophosphamide/aldophosphamide in whole blood |
| Q68202674 | Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites |
| Q34630267 | The effect of age on the pharmacokinetics of ifosfamide |
| Q68801422 | The effect of route of administration and fractionation of dose on the metabolism of ifosfamide |
| Q41478818 | Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture |
Search more.